Article
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.
Cancer research - 2 Jun 2025
Tikum Anjong Florence, Henning Nikita W, Pougoue Ketchemen Jessica, Doroudi Alireza, Babeker Hanan, Njotu Fabrice Ngoh, Nwangele Emmanuel, Monzer Alissar, Gray Bridget, Torlakovic Emina, Uppalapati Maruti, Fonge Humphrey
Abstract excerpt
EGFR is expressed in approximately 80% to 85% of colorectal cancers. Although anti-EGFR antibodies benefit some patients with colorectal cancer, tumors with Kirsten rat sarcoma viral oncogene (KRAS) or B-rapidly accelerated fibrosarcoma (BRAF), a proto-oncogene serine/threonine protein kinase, mutations are resistant. In this study, we developed a theranostic approach that uses an anti-EGFR antibody-drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.